CL2020000735A1 - Preparación de formas de dosificación sólida que comprenden anticuerpos por estratificación de solución/suspensión. - Google Patents

Preparación de formas de dosificación sólida que comprenden anticuerpos por estratificación de solución/suspensión.

Info

Publication number
CL2020000735A1
CL2020000735A1 CL2020000735A CL2020000735A CL2020000735A1 CL 2020000735 A1 CL2020000735 A1 CL 2020000735A1 CL 2020000735 A CL2020000735 A CL 2020000735A CL 2020000735 A CL2020000735 A CL 2020000735A CL 2020000735 A1 CL2020000735 A1 CL 2020000735A1
Authority
CL
Chile
Prior art keywords
dosage forms
solid dosage
solution
antibodies
preparation
Prior art date
Application number
CL2020000735A
Other languages
English (en)
Spanish (es)
Inventor
Felipe Varum
Rochow Laetitia Von
Carmen Wetzel
Roberto Bravo
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59923358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020000735(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of CL2020000735A1 publication Critical patent/CL2020000735A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2020000735A 2017-09-20 2020-03-20 Preparación de formas de dosificación sólida que comprenden anticuerpos por estratificación de solución/suspensión. CL2020000735A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17192260.2A EP3459528B1 (en) 2017-09-20 2017-09-20 Preparation of solid dosage forms comprising antibodies by solution/suspension layering

Publications (1)

Publication Number Publication Date
CL2020000735A1 true CL2020000735A1 (es) 2020-10-23

Family

ID=59923358

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000735A CL2020000735A1 (es) 2017-09-20 2020-03-20 Preparación de formas de dosificación sólida que comprenden anticuerpos por estratificación de solución/suspensión.

Country Status (26)

Country Link
US (2) US11826470B2 (https=)
EP (2) EP3459528B1 (https=)
JP (2) JP7204743B2 (https=)
KR (2) KR20200055711A (https=)
CN (1) CN111093635A (https=)
AR (1) AR112901A1 (https=)
AU (2) AU2018337493B2 (https=)
CA (1) CA3075862A1 (https=)
CL (1) CL2020000735A1 (https=)
CO (1) CO2020003070A2 (https=)
CR (2) CR20210203A (https=)
EA (1) EA202090640A8 (https=)
ES (1) ES2938609T3 (https=)
GE (4) GEAP202115318A (https=)
IL (2) IL272933B2 (https=)
JO (2) JOP20200064B1 (https=)
MA (1) MA50157A (https=)
MX (1) MX2020003032A (https=)
MY (1) MY209948A (https=)
PH (1) PH12020500353A1 (https=)
SA (1) SA520411573B1 (https=)
SG (1) SG11202002203YA (https=)
TW (1) TWI802592B (https=)
UA (1) UA129148C2 (https=)
WO (1) WO2019057562A1 (https=)
ZA (2) ZA202001752B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3459528B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
CN112263564B (zh) * 2020-10-30 2022-07-19 黄山中皇制药有限公司 一种喜炎平干混悬剂的制备方法
CN112107694B (zh) * 2020-10-30 2022-07-22 黄山中皇制药有限公司 一种喜炎平干混悬剂
CN116236463A (zh) * 2023-02-16 2023-06-09 山东省药学科学院 右酮洛芬缓释微丸胶囊及其制备方法
AU2024241638A1 (en) 2023-03-28 2025-10-09 Tillotts Pharma Ag Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
IT1241417B (it) 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
DK0590060T3 (da) 1991-06-21 1998-05-11 Univ Cincinnati Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling
DE69432309D1 (de) 1993-09-20 2003-04-24 Anadis Ltd Verfahren zur herstellung von immunoglobulinen aus colostrum und deren verwendung in pharmazeutischen zusammensetzungen
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
WO2000018500A1 (de) 1998-09-24 2000-04-06 Glatt Systemtechnik Dresden Gmbh Einrichtung zur herstellung eines schüttfähigen produktes und verfahren zur anwendung der einrichtung
CN1242060C (zh) 1997-12-20 2006-02-15 金克克国际有限公司 基体颗粒
US6074689A (en) 1998-03-10 2000-06-13 Immucell Corporation Colonic delivery of protein or peptide compositions
FI20000780A7 (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
EP1589951B1 (en) 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
CA2538064C (en) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
DE10353196A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
DE10353186A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
US20080254115A1 (en) 2004-05-19 2008-10-16 Rubino Orapin P Micropellet Containing Pellets and Method of Preparing Such Pellets
US20080220080A1 (en) 2005-03-29 2008-09-11 Röhm Gmbh Multiparticulate Pharmaceutical form Comprising Pellets with a Substance Having a Modular Effect in Relation to Active Ingredient Release
WO2006102965A1 (en) * 2005-03-29 2006-10-05 Evonik Röhm Gmbh Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance
KR101457223B1 (ko) 2005-06-07 2014-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 억제하는 안정적이고 가용성인 항체
ES2459018T3 (es) 2006-02-09 2014-05-07 Alba Therapeutics Corporation Formulaciones de efectores de la unión estrecha
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
EP2143424A4 (en) 2007-03-26 2013-07-31 Teikoku Seiyaku Kk ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
US20100239682A1 (en) * 2007-09-17 2010-09-23 Antoine Andremont Colonic delivery of antimicrobial agents
CA2615137A1 (en) * 2007-12-17 2009-06-17 Pharmascience Inc. Single layered controlled release therapeutic system
JP2011508755A (ja) 2008-01-03 2011-03-17 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 精製微生物リパーゼの顆粒を有する医薬組成物ならびに消化器疾患を予防又は治療する方法
KR102050040B1 (ko) 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
EP2769711A1 (en) 2008-07-10 2014-08-27 ESBATech, an Alcon Biomedical Research Unit LLC Methods and Compositions for Enhanced Delivery of Macromolecules
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物
EP2340812A1 (en) 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
AU2012230733B2 (en) * 2011-03-23 2016-10-20 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
AU2012234282B2 (en) 2011-03-28 2015-07-16 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
WO2014142938A1 (en) 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
FR3022462B1 (fr) * 2014-06-18 2018-04-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnfalpha
KR102790656B1 (ko) * 2015-05-04 2025-04-02 컨플루언스 파마슈티컬스, 엘엘씨 아캄프로세이트의 스프링클 제형
EP3459528B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering

Also Published As

Publication number Publication date
JOP20200064A1 (ar) 2020-03-17
SA520411573B1 (ar) 2023-12-19
IL272933B1 (en) 2025-02-01
CR20210203A (es) 2022-03-21
GEP20227351B (en) 2022-02-10
JP7204743B2 (ja) 2023-01-16
PH12020500353A1 (en) 2021-01-25
ZA202210822B (en) 2024-10-30
EP3459528B1 (en) 2022-11-23
AR112901A1 (es) 2019-12-26
US20240099980A1 (en) 2024-03-28
KR20200055711A (ko) 2020-05-21
CA3075862A1 (en) 2019-03-28
BR112020005460A2 (pt) 2020-09-24
JP2020534290A (ja) 2020-11-26
US20210030682A1 (en) 2021-02-04
US11826470B2 (en) 2023-11-28
MY209948A (en) 2025-08-14
EA202090640A8 (ru) 2021-12-28
IL272933A (en) 2020-04-30
BR112020005460A8 (pt) 2022-12-27
EP3684339A1 (en) 2020-07-29
CN111093635A (zh) 2020-05-01
ES2938609T3 (es) 2023-04-13
SG11202002203YA (en) 2020-04-29
EA202090640A1 (ru) 2020-06-15
CO2020003070A2 (es) 2020-04-13
AU2024219328A1 (en) 2024-09-19
AU2018337493A1 (en) 2020-03-19
UA129148C2 (uk) 2025-01-29
GEAP202215611A (en) 2022-12-12
MX2020003032A (es) 2020-07-22
EP3459528A1 (en) 2019-03-27
MA50157A (fr) 2020-07-29
IL318231A (en) 2025-03-01
JOP20200064B1 (ar) 2024-12-22
GEAP202115318A (en) 2021-09-10
KR20240137117A (ko) 2024-09-19
WO2019057562A1 (en) 2019-03-28
JP2023036901A (ja) 2023-03-14
TWI802592B (zh) 2023-05-21
JOP20240141A1 (ar) 2024-06-24
TW201914578A (zh) 2019-04-16
ZA202001752B (en) 2025-04-30
CR20200130A (es) 2020-08-06
GEP20237504B (en) 2023-04-25
IL272933B2 (en) 2025-06-01
AU2018337493B2 (en) 2024-09-12
AU2024219328B2 (en) 2026-03-26

Similar Documents

Publication Publication Date Title
CL2020000735A1 (es) Preparación de formas de dosificación sólida que comprenden anticuerpos por estratificación de solución/suspensión.
CL2022003769A1 (es) Anticuerpos de unión a cd3
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2017001217A1 (es) Conjugados de droga de anticuerpos.
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
MX383715B (es) Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
AR105089A1 (es) ANTICUERPOS ANTI-TAU(pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
EA201591133A1 (ru) СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19
MX349235B (es) Anticuerpos monoclonales específicos para el antígeno m2-1 del virus respiratorio sincicial (vrs).
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
AR112701A1 (es) Método para preparar una forma de dosificación sólida que comprende anticuerpos por granulación en húmedo, extrusión y esferonización
NI201900023A (es) 1 - arilnaftiridin-3-carboxamidas 7-sustituidas y su uso
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
AR098221A1 (es) Conjugados de anticuerpo anti-efna4-fármaco
AR089079A1 (es) Formulacion de anticuerpo anti-cd44
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
AR096455A1 (es) Vacuna para la malaria
CL2015000072A1 (es) Compuestos derivados de azaindol, inhibidores pi3k; metodo de preparacion; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento de tratornos inmunologicos, cancer y enfermedades cardiovasculares.
TH170283A (th) ฮิวแมไนซ์แอนติบอดีที่จดจำแอลฟา-ไซนูคลีน
TH170268A (th) แอนทิบอดีใหม่ที่ต้าน-ตัวรับ tslp ของมนุษย์
AR095869A1 (es) Anticuerpos humanos que se unen a la proteína g del rsv